Glimepirid Lek (Glimepiride)

Glimepirid Lek is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy in patients newly diagnosed with type 2 diabetes.
• May be combined with metformin or other oral antidiabetic agents for enhanced effect.
• Suitable for adults who are able to swallow tablets.
• May be considered when other sulfonylureas are not tolerated.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common

• Mild to moderate hypoglycemia, especially when meals are missed.
• Weight gain due to increased insulin activity.
• Nausea, abdominal discomfort, or dyspepsia.
• Dizziness or headache.

Serious

• Severe allergic reactions such as rash, itching, swelling, or anaphylaxis.
• Prolonged hypoglycemia leading to loss of consciousness or seizures.

Before starting Glimepirid Lek, certain clinical considerations and warnings should be reviewed to minimize risk.

• Assess renal and hepatic function; dose adjustment may be needed.
• Avoid use in patients with known hypersensitivity to sulfonylureas.
• Caution in the elderly due to increased risk of hypoglycemia.
• Monitor blood glucose regularly, especially when initiating therapy or changing dose.
• Use with caution during pregnancy or breastfeeding; benefits must outweigh potential risks.
• Consider cardiovascular status, as sulfonylureas may affect ischemic preconditioning.

Glimepirid Lek can interact with several medicines, influencing its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides (additive hypoglycemia risk).
• Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole) may raise glimepiride levels.
• Use with monoamine oxidase inhibitors may affect glucose control.

Use with caution

• Combination with insulin or other insulin secretagogues requires dose adjustments.
• Concomitant beta‑blockers may mask hypoglycemia symptoms.
• Loop diuretics can affect plasma glucose and potassium balance.
• NSAIDs may impair renal function, influencing drug clearance.